ArticleChinese medicine2025
Modified Guilu Erxian Glue regulates Treg immune function to suppress bone marrow failure in aplastic anemia mice.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Guilu Erxian Glue Restores Immune Homeostasis in Aplastic Anemia Mice by Regulating Treg Lineage Stability via the miRNA-17/10a and FasL/Fas Signaling Pathways.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAplastic anemia (AA) is an autoimmune disorder characterized by impaired immunosuppressive function and abnormal differentiation of regulatory T (Treg) cells. Immunosuppressive treatment (IST) is a primary treatment for AA. Our previous studies have suggested that Modified Guilu Erxian Glue (MGEG) could improve hematopoietic function through immune modulation. These results indicated that it should serve as an adjunct therapy in boosting the efficacy of IST for AA treatment. Nevertheless, the regulatory mechanisms of MGEG on the Treg cells were unclear. In this study, we aimed to investigate the mechanisms of the combination therapy of IST and MGEG on the function and differentiation of Treg cells, contributing to alleviate the hematopoietic dysfunction in immune-mediated AA mice.
methodsAn AA mouse model was established using 3.5 Gy
resultsHPLC-ESI/MS identified 30 compounds from the aqueous extract of MGEG, including amentoflavone, berberine, and ononin. The combined treatment of IST + MGEG improved the hematopoietic function of AA mice, as indicated by restored blood cell counts and reduced bone marrow adiposity. It also rebalanced the Th1/Th2 and Th17/Treg ratios, increased the proportion of Treg B cells, and ameliorated bone marrow inflammatory status. Furthermore, the combination treatment could inhibit Treg cell apoptosis through downregulating the expression of Fas and levels of Cleaved-Caspase-3/8 while upregulating p-Bcl-2. It also enhanced p-STAT5 and Foxp3 protein levels, contributed to promoting naïve T cell differentiation into Treg cells. Additionally, IST combined with MGEG reduced miR-17-5p and HIF-1α expression in CD4
conclusionsCompared with the IST + EP or IST alone, the combination treatment of IST + MGEG further improved hematopoietic function in AA mice. These effects should involve regulating the differentiation of Treg cells through intervening in the activation of IL-2/STAT5 signaling pathway, improving the immune regulatory function of Treg cells by intervening in the miR-17-5p/Eos signaling pathway, and inhibiting Fas/FasL mediated apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.